MiNK Therapeutics Soars 538% After Cancer Breakthrough - Wall Street Pit

MiNK Therapeutics Soars 538% After Cancer Breakthrough - Wall Street Pit

MiNK Therapeutics’ (INKT) stock surged 538% to $49.53 after a patient with treatment-resistant testicular cancer achieved complete remission using agenT-797, lasting over two years without serious side effects. The company’s Phase 2 trial in gastric cancer showed immune activation and extended survival beyond 12 months in patients who failed prior…

Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy - BioTuesdays

MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer, following treatment with the company’s allogeneic iNKT cell therapy, agent-797. The publication titled Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor, presents a patient case …